Management of Gastric Biopsy with No Specific Abnormalities or Helicobacter Pylori
For a gastric biopsy showing no specific diagnostic abnormalities and no Helicobacter pylori organisms, no specific treatment is required, but clinical correlation and consideration of false-negative H. pylori testing should guide further management.
Assessment of H. pylori Status
- When H. pylori is not detected on initial histology, consider potential false-negative results, especially if the patient was on proton pump inhibitors (PPIs) prior to biopsy 1
- PPIs should ideally be stopped 2 weeks before testing for H. pylori by culture, histology, rapid urease test, urea breath test, or stool test 1
- If PPI discontinuation was not done prior to biopsy, validated IgG serology can be performed as it is not affected by PPI use 1
Biopsy Technique Considerations
- The Sydney System protocol recommends 5 biopsies from specific gastric locations to optimize H. pylori detection 1
- Biopsies should include samples from the lesser and greater curve of the antrum, lesser curvature of the corpus, greater curvature of the corpus, and incisura angularis 1
- Routine immunohistochemistry for H. pylori is not necessary for all gastric biopsies but may be considered for unexplained gastritis or previously treated patients with likely low organism density 2
Clinical Correlation
- Normal gastric mucosa without H. pylori indicates an extremely low risk of both peptic ulcer disease and gastric cancer, which is clinically relevant information 3, 4
- In patients with dyspeptic symptoms but normal-appearing gastric mucosa on endoscopy, the American Gastroenterological Association recommends routine biopsies for H. pylori detection if infection status is unknown 1
- The presence of normal, healthy gastric mucosa with duodenal or gastric ulcer suggests other etiologies such as NSAIDs or aspirin use 3
Differential Diagnosis for H. pylori Negative Gastritis
- Consider lymphocytic gastritis, inflammatory bowel disease, vasculitis, granulomatous disease, or viral infections such as cytomegalovirus (CMV) or Epstein-Barr virus (EBV) 5
- Medication-induced gastropathy should be excluded, including antibiotics used for H. pylori eradication or other common medications 5
- When all known causes have been excluded, the term "idiopathic focal/diffuse gastritis" can be used 5
Follow-up Recommendations
- If clinical suspicion for H. pylori remains high despite negative histology, consider alternative testing methods such as urea breath test or stool antigen test 1
- For patients with persistent dyspeptic symptoms and negative H. pylori testing, management should focus on symptomatic treatment and consideration of functional dyspepsia 1
- In patients with risk factors for gastric malignancy but negative initial biopsies, consider repeat endoscopy with more extensive sampling if symptoms persist 3, 4
Special Considerations
- In immunocompromised patients with dyspepsia, routine gastric biopsies are strongly recommended even with normal-appearing mucosa, as conditions like cytomegalovirus infection may be present without visible lesions 1
- If standard susceptibility testing is not possible but treatment for H. pylori is being considered, molecular tests can be used to detect H. pylori and clarithromycin and/or fluoroquinolone resistance directly on gastric biopsies 1